🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL

RecruitingPhase 1, Phase 2Ages 2 Years - 18 YearsAllKara Yakhteh Tajhiz Azma Company
NCT06635330 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this clinical trial is to evaluate the safety and efficacy of CD19 CAR-T cells in pediatric patients of all genders, aged 2 to 18 years, with relapsing or refractory B cell acute lymphoblastic leukemia (r/r B-ALL). The main questions it aims to answer are as following: 1. What is the percentage of patients with overall remission rate (ORR) of complete response (CR) or complete remission with incomplete blood count recovery (CRi)? 2. What is the rate of Event-free survival at first month and 2-3 months after intervention? 3. What is the rate of Overall survival at first month and at 3 months after the intervention?

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Ages 2 to 18 years with relapsed or refractory CD19+ B-ALL * Presence of disease in the bone marrow * Able to tolerate the apheresis process * Life expectancy \> 12 weeks * Lansky or Karnofsky score \> 50% * At least 7 days passed since the last chemotherapy and the last treatment with corticosteroids * Informed consent * Having potential donor for stem cell transplantation Exclusion Criteria: * Presence of active malignancy other than the disease under study * Chloroma and leukemic infiltration on MRI or significant neurological symptoms * Any CNS disorder * Presence of active GVHD * Radiation therapy within last 14 days * History of Anti-CD19 or Anti-CD20 therapy * Donor lymphocyte injection or other cell therapy methods within the last 30 days * Presence of severe active infection * Organ dysfunction
💊

What it tests

  • anti-CD19 CAR T cell therapy
📍

Where

1 site
Pediatric cell and gene therapy research center, Children medical center
Tehran, Iran
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy